PeptideStack
5.2kquestions
20kanswers
220users

What should a two-person split record so an escrowed payment dispute can be settled?

Asked 12 Feb 2025Modified 14 months agoViewed 27k times
31

What I am working with: a two-person split · an escrowed payment.

I want a method I can write down and repeat, not a rule of thumb.

I would rather over-engineer this than discover a problem later, within reason.

Which parts of this are load-bearing and which parts are habit?

group-buy
group-buy

Pooled purchasing: how the economics work, what trust structure a pool needs, splitting a single tested lot, and the failure modes when the…

41 questions
payment-privacy
payment-privacy

Payment mechanics and their privacy properties: why suppliers ask for stablecoin transfers, what an on-chain transfer reveals, confirmation…

31 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
shareeditfollowflag
OB
askedone_ml_bac18k2712 Feb 2025
3Is this about one lot or about a supplier across lots? Different questions. – Dr_Bram_Verhoeven 3 months ago
add a comment

4 Answers

Accepted answer first, then by votes
135

Accepted answer

The short version: real savings on carriage and unit price, real risks in custody, splitting and the legal position of whoever receives it.

The real saving is in carriage and in unit price breaks, not in the compound itself. Carriage on a single larger consignment is typically a fraction of the sum of individual shipments, and that is where most of the arithmetic comes from.

Cost per milligram, adjusted honestly

StepValueNote
Vial price, 10 mg nominal£34.00As advertised
Nominal cost per mg£3.4034 ÷ 10
Measured content9.2 mgIndependent content assay
Cost per actual mg£3.7034 ÷ 9.2
Dead-space loss, 20 draws4 %80 µL of a 2 mL fill
Cost per delivered mg£3.853.70 ÷ 0.96
First vial, with £110 assay£14.85Testing dominates a single vial

Whoever receives the consignment is the importer of record in most jurisdictions, regardless of who paid. That is a legal position rather than an administrative one and it does not divide among contributors.

Importer-of-record status attaches to the receiving party in most customs regimes and is not divisible among contributors.

The caveat is legal rather than analytical: onward supply is treated differently from personal importation in many jurisdictions and the difference is not a technicality.

Split sealed vials only. Anything else breaks the certificate and the closure together.

edited 26 Mar 2025 by thabo_maseko — reworded for clarity after a comment

shareimprove this answerflag
TM
answered · acceptedthabo_maseko28k3815 Mar 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
54

Answering this needs to know whether the split is of sealed vials or of anything opened, since those are different situations entirely.

Ordering a single lot for the whole group is the analytical advantage: one independent submission then characterises everyone's material, which spreads the cost of testing across the participants.

Specifically, custody is the risk. One person holds the money before the order and the material after it, and there is no mechanism to compel anything if it goes wrong.

A single lot across all participants means one independent submission characterises the whole consignment, which is the strongest analytical argument for the arrangement.

There is no recourse mechanism in an informal arrangement. That is the risk, and it cannot be structured away entirely.

Write down who paid what and who received what, before it ships.

shareimprove this answerflag
LB
answeredlaminar_bench69k574 Mar 2025
Small correction: carriage amortises across the order, which changes small-order economics entirely. – Dr_Tomas_Kral 10 days ago
8The point about the code being on the glass rather than the box is worth its own thread. – forty_two_c 9 months ago
add a comment
39

Answer first: the economics work and the counterparty risk is the whole problem, because a group buy concentrates money and material in one person's hands.

Keep a written record: who contributed, what was ordered, which lot arrived, how many vials each person received and when. It resolves disputes and it is the only documentation that will exist.

Splitting sealed vials preserves the manufacturer's container closure and the lot traceability. Splitting anything that has been opened, reconstituted or repackaged breaks both and no certificate follows the material after that point.

Whoever receives it is the importer. Make sure that person knows.

shareimprove this answerflag
TM
answeredthabo_maseko28k3821 Feb 2025
6Adding for future readers: ask for the lot-specific certificate before ordering, not after. – tenth_of_a_unit 43 days ago
add a comment
32

The relevant point is that whoever receives the consignment is the importer, with whatever that means in their jurisdiction.

Onward distribution — even at cost, even among people who paid — may be a different legal act from personal importation in many jurisdictions. It is worth understanding the local position rather than assuming.

One lot for the group means one submission covers everybody. That is the real advantage.

shareimprove this answerflag
WO
answeredw_okoye43k13710 Jun 2025
5Does the same reasoning hold for a group order, where one lot covers everybody? – forty_two_c 8 months ago
4Same experience here, different supplier. – tandem_gradient 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.